AmerisourceBergen Corp. (ABC, Financial) filed Annual Report for the period ended 2010-09-30.
Amerisourcebergen Corp. has a market cap of $8.67 billion; its shares were traded at around $31.11 with a P/E ratio of 14.3 and P/S ratio of 0.1. The dividend yield of Amerisourcebergen Corp. stocks is 1.3%. Amerisourcebergen Corp. had an annual average earning growth of 14.4% over the past 10 years. GuruFocus rated Amerisourcebergen Corp. the business predictability rank of 4.5-star.ABC is in the portfolios of David Williams of Columbia Value and Restructuring Fund, John Keeley of Keeley Fund Management, Jim Simons of Renaissance Technologies LLC, George Soros of Soros Fund Management LLC, Jeremy Grantham of GMO LLC, Bruce Kovner of Caxton Associates, Steven Cohen of SAC Capital Advisors, Mario Gabelli of GAMCO Investors.
Customers. We have a diverse customer base that includes institutional and retail healthcare providers as well as pharmaceutical manufacturers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physicians and physician group practices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies and pharmacy departments of supermarkets and mass merchandisers. We are typically the primary source of supply for our healthcare provider customers. Our manufacturing customers include branded, generic and biotech manufacturers of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers. In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers. In fiscal 2010, total revenue was comprised of 70% institutional customers and 30% retail customers.
In fiscal 2010, Medco Health Solutions, Inc., our largest customer, accounted for 18% of our revenue. No other individual customer accounted for more than 5% of our fiscal 2010 revenue. Our top ten customers represented approximately 42% of fiscal 2010 revenue. In addition, we have contracts with group purchasing organizations (GPOs), each of which functions as a purchasing agent on behalf of its members, who are healthcare providers. Approximately 10% of our revenue in fiscal 2010 was derived from our three largest GPO relationships. The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.
Suppliers. We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in fiscal 2010. The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers. We believe that our relationships with our suppliers are good. The ten largest suppliers in fiscal 2010 accounted for approximately 50% of our purchases.
Read the The complete Report
Amerisourcebergen Corp. has a market cap of $8.67 billion; its shares were traded at around $31.11 with a P/E ratio of 14.3 and P/S ratio of 0.1. The dividend yield of Amerisourcebergen Corp. stocks is 1.3%. Amerisourcebergen Corp. had an annual average earning growth of 14.4% over the past 10 years. GuruFocus rated Amerisourcebergen Corp. the business predictability rank of 4.5-star.ABC is in the portfolios of David Williams of Columbia Value and Restructuring Fund, John Keeley of Keeley Fund Management, Jim Simons of Renaissance Technologies LLC, George Soros of Soros Fund Management LLC, Jeremy Grantham of GMO LLC, Bruce Kovner of Caxton Associates, Steven Cohen of SAC Capital Advisors, Mario Gabelli of GAMCO Investors.
Highlight of Business Operations:
Pharmaceutical sales in the United States, as recently estimated by IMS Healthcare, Inc. (IMS), an independent third party provider of information to the pharmaceutical and healthcare industry, are expected to grow between 3% and 5% in calendar 2011. IMS expects that certain sectors of the market, such as biotechnology and other specialty and generic pharmaceuticals, will grow faster than the overall market. Additionally, IMS expects the U.S. pharmaceutical industry to grow annually between 2% and 5% through 2014.Customers. We have a diverse customer base that includes institutional and retail healthcare providers as well as pharmaceutical manufacturers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physicians and physician group practices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies and pharmacy departments of supermarkets and mass merchandisers. We are typically the primary source of supply for our healthcare provider customers. Our manufacturing customers include branded, generic and biotech manufacturers of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers. In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers. In fiscal 2010, total revenue was comprised of 70% institutional customers and 30% retail customers.
In fiscal 2010, Medco Health Solutions, Inc., our largest customer, accounted for 18% of our revenue. No other individual customer accounted for more than 5% of our fiscal 2010 revenue. Our top ten customers represented approximately 42% of fiscal 2010 revenue. In addition, we have contracts with group purchasing organizations (GPOs), each of which functions as a purchasing agent on behalf of its members, who are healthcare providers. Approximately 10% of our revenue in fiscal 2010 was derived from our three largest GPO relationships. The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.
Suppliers. We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in fiscal 2010. The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers. We believe that our relationships with our suppliers are good. The ten largest suppliers in fiscal 2010 accounted for approximately 50% of our purchases.
Read the The complete Report
